Pharmacological Migraine Prophylaxis Guidelines
Guidelines for pharmacological prophylaxis of migraines chart
Guidelines for pharmacological prophylaxis of migraines chart
A systematic review was published focusing on migraine treatment and prevention using neurostimulation methods.
A smartphone application delivering guided progressive muscle relaxation was a both an accessible and acceptable form of therapy for patients with migraine.
During the study, participants completed a survey every evening pertaining to migraine occurrence and possible migraine predictors on an iPhone specific application.
INP104 uses proprietary technology to deliver a lower dose (1.45mg) of dihydroergotamine mesylate (DHE) to the upper nasal space.
While it does not influence migraine severity, the renin-angiotensin system (RAS) has an important role in the pathophysiology of migraine.
Occipital nerve stimulation has been proposed to treat refractory chronic cluster headache but this study aimed to evaluate ONS long-term efficacy in rCCH.
The HER-MES study included 777 adult patients suffering from at least 4 migraine days/month and who were naïve to, not suitable for, or had previously failed up to 3 prophylactic treatments.
This phase 3, randomized, double-blind, placebo-controlled study assessed the efficacy and safety of IV infusion of eptinezumab to prevent migraine in adults with chronic migraine.
Qtrypta delivers zolmitriptan, a selective 5-HT1B/1D receptor agonist, using the Company’s proprietary Adhesive Dermally-Applied Microarray (ADAM) technology that consists of a drug-coated microneedle patch.